Home › Compare › RASP vs EQR

RASP vs EQR: Dividend Comparison 2026

RASP yields 400000.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RASP wins by $5.011119029548644e+32M in total portfolio value
10 years
RASP
RASP
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full RASP calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — RASP vs EQR

📍 RASP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRASPEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RASP + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RASP pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RASP
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, RASP beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RASP + EQR for your $10,000?

RASP: 50%EQR: 50%
100% EQR50/50100% RASP
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RASP
No analyst data
Altman Z
-908.0
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RASP buys
0
EQR buys
0
No recent congressional trades found for RASP or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRASPEQR
Forward yield400000.00% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$5.011119029548644e+32M$47.8K ✓
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00 ✓$5,475.61
Total dividends collected$5.010957816668433e+32M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RASP vs EQR ($10,000, DRIP)

YearRASP PortfolioRASP Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$40,010,700$40,000,000.00$11,380$679.82+$40.00M → RASP
2$149,615,521,729$149,572,710,280.37$13,014$837.25+$149615.51M → RASP
3$522,880,052,725,200$522,719,964,116,949.25$14,961$1,036.20+$522880052.71M → RASP
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$17,297$1,289.22+$1707862989289.03M → RASP
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$20,121$1,613.15+$5213509402845684.00M → RASP
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$23,561$2,030.84+$14874219058409543680.00M → RASP
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$27,783$2,573.54+$3.966119623405075e+22M → RASP
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$33,013$3,284.39+$9.88384363503273e+25M → RASP
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$39,547$4,223.51+$2.302052364743449e+29M → RASP
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$47,791$5,475.61+$5.011119029548644e+32M → RASP

RASP vs EQR: Complete Analysis 2026

RASP — Stock

Actavia Life Sciences, Inc. is a biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. It also develops small molecule drug candidates that focus on treating acute myeloid leukemia. The company was founded in 2013 and is headquartered in New York, NY.

Full RASP Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RASP vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RASP vs SCHDRASP vs JEPIRASP vs ORASP vs KORASP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.